Consistent with this, in the phase II part of our study, ieramilimab in combination with spartalizumab elicited durable responses not only in melanoma, but also in patients with mesothelioma and renal-cell carcinoma who had received prior treatment with anti-PD-(L)1 inhibitors.34 The clinical impact of targeting LAG-3 in combination with other immunotherapies warrants further investigation. This evidence concerns the gene LAG3 and renal cell carcinoma.